Drug details

Uptravi (uptravi selexipag tablets)

type of PAH, Prostacyclin Agonists

Uptravi (selexipag) is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• pale skin,
• lightheadedness,
• shortness of breath,
• cold hands and feet,
• severe shortness of breath,
• sweating,
• unusual tiredness,
• chest pain, and
• anxiety,
• cough with foamy mucus,
• fast or uneven heart rate
• grasping for breath,

The following drugs are related to Uptravi, either as a replacement or used together:

• Adcirca (tadalafil tablets)
• Adempas (riociguat tablets)
• Alyq (tadalafil tablets)
• Letairis (ambrisentan tablets)
• Tracleer (bosentan)
• Veletri (epoprostenol powder for intravenous administration)
• Flolan (epoprostenol sodium)
• Ventavis (iloprost)
• Remodulin (treprostinil sodium)
• Revatio (sildenafil citrate)
• Viagra (sildenafil citrate)
• Tyvaso DPI (treprostinil inhalation powder)
• Tyvaso (treprostinil inhalation solution)